Impact of Platinum-based Cancer Treatment on Endothelial Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-18

Study Completion Date

2020-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this research we investigate endothelial function in cancer patients who received platinum based chemotherapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of the study is to evaluate endothelial function in patients with platinum-based versus non-platinum-based chemotherapy.

Endothelial function was evaluated via Angioscan( the apparatus that evaluate the stiffness of vessels by pulse wave velocity) and serum levels of endothelial nitric oxide synthase (ENOS),endothelin1.

Patients with gastrointestinal, ovarian, bladder and brest cancer would be included.

Patients with malignancies were followed-up from 2 weeks to 3 month after start of chemotherapy, Medical records and hospital databases were searched for all the patients treated with different chemotherapy treatment for any kind of cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Blood Pressure Cardiovascular Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has solid cancer
* Subject is expected to start chemotherapy

Exclusion Criteria

* Pregnancy and lactation
* Severe impaired kidney function
* Severe hepatic impairment
* Mental disease
* Acute myocardial infarction 28 days ago or earlier
* Acute Cerebrovascular Event 1 month ago or earlier
* Rhythm disturbance that complicate pulse wave velocity evaluation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dmitry Shchekochikhin, PhD

Role: PRINCIPAL_INVESTIGATOR

I.M. Sechenov First Moscow State Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Olga Andreeva

Moscow, , Russia

Site Status

First Moscow State Medical University.